Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Schedule an appointment today

Call to Schedule: 1-866-UH4-CARE
Digestive Health Research
Visit the Research & Education Institute

Novo Nordisk Study

This study is currently closed to enrollment.

Efficacy and Safety Investigation of NNC0194-0499 Co-administered with Semaglutide in Subjects with Non-Alcoholic Steatohepatitis: A Dose-Ranging, Placebo-Controlled Trial

liver illustration
AGE: 18+ years old
SEX AT BIRTH: All
TYPE: Interventional Drug Study
CONDITION: Nonalcoholic Steatohepatitis (NASH)
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center

Study Purpose

The purpose of this research study is to see if a combination of 2 medicines (NNC0194-0499 and semaglutide) can reduce liver damage in patients with NASH.